We respond to National Cancer Patient Experience Survey

We have responded to National Cancer Patient Experience Survey showing satisfaction with NHS cancer care is at a record high. ...

27 July 2018

We welcome the new Health Secretary’s commitments to workforce, technology and prevention

The Secretary of State for Health and Social Care, Matt Hancock today outlined his commitments to workforce, technology and prevention, in his first...

20 July 2018

"Wonderful" impact of breast cancer treatment on fertility included in updated NICE guidance

Responding to the publication of NICE’s updated guidance for early and locally advanced breast cancer, Samia al Qadhi, Chief Executive of Breast...

18 July 2018

More research needed to understand "slight increase in breast cancer risk for cabin crew staff"

Responding to the news that flight attendants are more likely to develop several forms of cancer than the average person, Addie Mitchell, Clinical...

26 June 2018

Study adds "interesting dimension" to link between obesity and breast cancer risk

Responding to new evidence from the Institute of Cancer Research suggesting that higher BMIs in young women reduce their risk of breast cancer,...

21 June 2018

Our response to new audit showing women over 70 are less likely to undergo surgery, radiotherapy and chemotherapy than women aged 50 to 69

The figures were published today by the National Audit of Breast Cancer in Older Patients (NABCOP), which is carried out by the Royal College of...

19 June 2018

"Worrying discord" between breast cancer treatment for women over and under 70

Responding to a new review by the Royal College of Surgeons and the Association of Breast Surgery revealing that older women are less likely to...

19 June 2018

Breast Cancer Care CEO responds to "appalling" reconstruction surgery decisions

Responding to a new report revealing hundreds of women with breast cancer are being denied or rushed into surgery as policies restrict breast...

18 June 2018

Breast Cancer Care CEO responds to "short-sighted" decision on drug

Responding to the announcement by NICE to not recommend Perjeta (pertuzumab) for routine NHS use after surgery for early HER2-positive breast cancer...

15 June 2018